Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 74 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Follow-Up Questions
Who is the CEO of Janux Therapeutics Inc?
Dr. David Campbell is the President of Janux Therapeutics Inc, joining the firm since 2017.
What is the price performance of JANX stock?
The current price of JANX is $27.01, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Janux Therapeutics Inc?
Janux Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Janux Therapeutics Inc market cap?
Janux Therapeutics Inc's current market cap is $1.6B
Is Janux Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Janux Therapeutics Inc, including 7 strong buy, 13 buy, 1 hold, 0 sell, and 7 strong sell
